Treatment of glioma by engineered interleukin 4-secreting cells

The ability of interleukin-4 (IL-4) to mediate an antitumor response to human gliomas was studied in vivo in nude mice. To allow the effect of IL-4 to be exerted over a relatively short distance and at an optimal concentration, a transfected tumor cell line expressing a high level of IL-4 was used i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 1993-07, Vol.53 (13), p.3125-3128
Hauptverfasser: YU, J. S, WEI, M. X, CHIOCCA, E. A, MARTUZA, R. L, TEPPER, R. I
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3128
container_issue 13
container_start_page 3125
container_title Cancer research (Chicago, Ill.)
container_volume 53
creator YU, J. S
WEI, M. X
CHIOCCA, E. A
MARTUZA, R. L
TEPPER, R. I
description The ability of interleukin-4 (IL-4) to mediate an antitumor response to human gliomas was studied in vivo in nude mice. To allow the effect of IL-4 to be exerted over a relatively short distance and at an optimal concentration, a transfected tumor cell line expressing a high level of IL-4 was used in mixed tumor transplantation assays. There was a significant inhibition of growth of the U87 human glioma line when the IL-4-secreting cell line, LT-1, was implanted s.c. with the glioma in 5 nude mice when compared to contralateral control tumors consisting of the U87 glioma and IL-4-negative control cells. In addition, there was a prolongation of survival when U87 along with IL-4-secreting cells were implanted intracerebrally in 12 nude mice compared to 12 control nude mice implanted with U87 and IL-4-negative control cells and 11 control animals receiving U87 alone. Histological analysis 4 days after i.c. inoculation revealed the presence of a dramatic eosinophil infiltrate and tumor necrosis. The absence of viable glioma cells as well as resolution of inflammation 19 days after treatment suggests the potential for complete tumor regression without ongoing inflammatory sequelae resulting from cytokine treatment.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_75807158</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75807158</sourcerecordid><originalsourceid>FETCH-LOGICAL-h269t-9f85208eb69c36d93c571f4ea7be8bfc9efc7a88c295204074017235daed69ff3</originalsourceid><addsrcrecordid>eNo9j01LxDAYhIMo67r6E4QcxFshn01yEll0FRa8rOeSpm9qtE3XpD3sv7di8TQM8zDMnKE1lVwXSgh5jtaEEF1Iodglusr5c7aSErlCK82pYYys0cMhgR17iCMePG67MPQW1ycMsQ0RIEGDQxwhdTB9hYhFkcElGENssYOuy9fowtsuw82iG_T-_HTYvhT7t93r9nFffLDSjIXxWjKioS6N42VjuJOKegFW1aBr7wx4p6zWjpmZE0QJQhXjsrHQlMZ7vkH3f73HNHxPkMeqD_l3gY0wTLlSUhNFpZ7B2wWc6h6a6phCb9OpWh7P-d2S2-xs55ONLuR_TGhCqKH8B2FzX14</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75807158</pqid></control><display><type>article</type><title>Treatment of glioma by engineered interleukin 4-secreting cells</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>YU, J. S ; WEI, M. X ; CHIOCCA, E. A ; MARTUZA, R. L ; TEPPER, R. I</creator><creatorcontrib>YU, J. S ; WEI, M. X ; CHIOCCA, E. A ; MARTUZA, R. L ; TEPPER, R. I</creatorcontrib><description>The ability of interleukin-4 (IL-4) to mediate an antitumor response to human gliomas was studied in vivo in nude mice. To allow the effect of IL-4 to be exerted over a relatively short distance and at an optimal concentration, a transfected tumor cell line expressing a high level of IL-4 was used in mixed tumor transplantation assays. There was a significant inhibition of growth of the U87 human glioma line when the IL-4-secreting cell line, LT-1, was implanted s.c. with the glioma in 5 nude mice when compared to contralateral control tumors consisting of the U87 glioma and IL-4-negative control cells. In addition, there was a prolongation of survival when U87 along with IL-4-secreting cells were implanted intracerebrally in 12 nude mice compared to 12 control nude mice implanted with U87 and IL-4-negative control cells and 11 control animals receiving U87 alone. Histological analysis 4 days after i.c. inoculation revealed the presence of a dramatic eosinophil infiltrate and tumor necrosis. The absence of viable glioma cells as well as resolution of inflammation 19 days after treatment suggests the potential for complete tumor regression without ongoing inflammatory sequelae resulting from cytokine treatment.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>PMID: 8319220</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adjuvants, Immunologic - pharmacology ; Animals ; Antineoplastic agents ; Biological and medical sciences ; Brain Neoplasms - therapy ; Female ; Glioma - therapy ; Humans ; Immunotherapy ; Injections, Intraventricular ; Injections, Subcutaneous ; Interleukin-4 - pharmacology ; Interleukin-4 - secretion ; Medical sciences ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Neoplasm Transplantation ; Pharmacology. Drug treatments ; Plasmacytoma - pathology ; Plasmacytoma - secretion ; Rats ; Recombinant Proteins - pharmacology ; Recombinant Proteins - secretion</subject><ispartof>Cancer research (Chicago, Ill.), 1993-07, Vol.53 (13), p.3125-3128</ispartof><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=4800191$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8319220$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>YU, J. S</creatorcontrib><creatorcontrib>WEI, M. X</creatorcontrib><creatorcontrib>CHIOCCA, E. A</creatorcontrib><creatorcontrib>MARTUZA, R. L</creatorcontrib><creatorcontrib>TEPPER, R. I</creatorcontrib><title>Treatment of glioma by engineered interleukin 4-secreting cells</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>The ability of interleukin-4 (IL-4) to mediate an antitumor response to human gliomas was studied in vivo in nude mice. To allow the effect of IL-4 to be exerted over a relatively short distance and at an optimal concentration, a transfected tumor cell line expressing a high level of IL-4 was used in mixed tumor transplantation assays. There was a significant inhibition of growth of the U87 human glioma line when the IL-4-secreting cell line, LT-1, was implanted s.c. with the glioma in 5 nude mice when compared to contralateral control tumors consisting of the U87 glioma and IL-4-negative control cells. In addition, there was a prolongation of survival when U87 along with IL-4-secreting cells were implanted intracerebrally in 12 nude mice compared to 12 control nude mice implanted with U87 and IL-4-negative control cells and 11 control animals receiving U87 alone. Histological analysis 4 days after i.c. inoculation revealed the presence of a dramatic eosinophil infiltrate and tumor necrosis. The absence of viable glioma cells as well as resolution of inflammation 19 days after treatment suggests the potential for complete tumor regression without ongoing inflammatory sequelae resulting from cytokine treatment.</description><subject>Adjuvants, Immunologic - pharmacology</subject><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Brain Neoplasms - therapy</subject><subject>Female</subject><subject>Glioma - therapy</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Injections, Intraventricular</subject><subject>Injections, Subcutaneous</subject><subject>Interleukin-4 - pharmacology</subject><subject>Interleukin-4 - secretion</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Nude</subject><subject>Neoplasm Transplantation</subject><subject>Pharmacology. Drug treatments</subject><subject>Plasmacytoma - pathology</subject><subject>Plasmacytoma - secretion</subject><subject>Rats</subject><subject>Recombinant Proteins - pharmacology</subject><subject>Recombinant Proteins - secretion</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9j01LxDAYhIMo67r6E4QcxFshn01yEll0FRa8rOeSpm9qtE3XpD3sv7di8TQM8zDMnKE1lVwXSgh5jtaEEF1Iodglusr5c7aSErlCK82pYYys0cMhgR17iCMePG67MPQW1ycMsQ0RIEGDQxwhdTB9hYhFkcElGENssYOuy9fowtsuw82iG_T-_HTYvhT7t93r9nFffLDSjIXxWjKioS6N42VjuJOKegFW1aBr7wx4p6zWjpmZE0QJQhXjsrHQlMZ7vkH3f73HNHxPkMeqD_l3gY0wTLlSUhNFpZ7B2wWc6h6a6phCb9OpWh7P-d2S2-xs55ONLuR_TGhCqKH8B2FzX14</recordid><startdate>19930701</startdate><enddate>19930701</enddate><creator>YU, J. S</creator><creator>WEI, M. X</creator><creator>CHIOCCA, E. A</creator><creator>MARTUZA, R. L</creator><creator>TEPPER, R. I</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19930701</creationdate><title>Treatment of glioma by engineered interleukin 4-secreting cells</title><author>YU, J. S ; WEI, M. X ; CHIOCCA, E. A ; MARTUZA, R. L ; TEPPER, R. I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h269t-9f85208eb69c36d93c571f4ea7be8bfc9efc7a88c295204074017235daed69ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Adjuvants, Immunologic - pharmacology</topic><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Brain Neoplasms - therapy</topic><topic>Female</topic><topic>Glioma - therapy</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Injections, Intraventricular</topic><topic>Injections, Subcutaneous</topic><topic>Interleukin-4 - pharmacology</topic><topic>Interleukin-4 - secretion</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Nude</topic><topic>Neoplasm Transplantation</topic><topic>Pharmacology. Drug treatments</topic><topic>Plasmacytoma - pathology</topic><topic>Plasmacytoma - secretion</topic><topic>Rats</topic><topic>Recombinant Proteins - pharmacology</topic><topic>Recombinant Proteins - secretion</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YU, J. S</creatorcontrib><creatorcontrib>WEI, M. X</creatorcontrib><creatorcontrib>CHIOCCA, E. A</creatorcontrib><creatorcontrib>MARTUZA, R. L</creatorcontrib><creatorcontrib>TEPPER, R. I</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YU, J. S</au><au>WEI, M. X</au><au>CHIOCCA, E. A</au><au>MARTUZA, R. L</au><au>TEPPER, R. I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of glioma by engineered interleukin 4-secreting cells</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>1993-07-01</date><risdate>1993</risdate><volume>53</volume><issue>13</issue><spage>3125</spage><epage>3128</epage><pages>3125-3128</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>The ability of interleukin-4 (IL-4) to mediate an antitumor response to human gliomas was studied in vivo in nude mice. To allow the effect of IL-4 to be exerted over a relatively short distance and at an optimal concentration, a transfected tumor cell line expressing a high level of IL-4 was used in mixed tumor transplantation assays. There was a significant inhibition of growth of the U87 human glioma line when the IL-4-secreting cell line, LT-1, was implanted s.c. with the glioma in 5 nude mice when compared to contralateral control tumors consisting of the U87 glioma and IL-4-negative control cells. In addition, there was a prolongation of survival when U87 along with IL-4-secreting cells were implanted intracerebrally in 12 nude mice compared to 12 control nude mice implanted with U87 and IL-4-negative control cells and 11 control animals receiving U87 alone. Histological analysis 4 days after i.c. inoculation revealed the presence of a dramatic eosinophil infiltrate and tumor necrosis. The absence of viable glioma cells as well as resolution of inflammation 19 days after treatment suggests the potential for complete tumor regression without ongoing inflammatory sequelae resulting from cytokine treatment.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>8319220</pmid><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-5472
ispartof Cancer research (Chicago, Ill.), 1993-07, Vol.53 (13), p.3125-3128
issn 0008-5472
1538-7445
language eng
recordid cdi_proquest_miscellaneous_75807158
source MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals
subjects Adjuvants, Immunologic - pharmacology
Animals
Antineoplastic agents
Biological and medical sciences
Brain Neoplasms - therapy
Female
Glioma - therapy
Humans
Immunotherapy
Injections, Intraventricular
Injections, Subcutaneous
Interleukin-4 - pharmacology
Interleukin-4 - secretion
Medical sciences
Mice
Mice, Inbred BALB C
Mice, Nude
Neoplasm Transplantation
Pharmacology. Drug treatments
Plasmacytoma - pathology
Plasmacytoma - secretion
Rats
Recombinant Proteins - pharmacology
Recombinant Proteins - secretion
title Treatment of glioma by engineered interleukin 4-secreting cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A53%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20glioma%20by%20engineered%20interleukin%204-secreting%20cells&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=YU,%20J.%20S&rft.date=1993-07-01&rft.volume=53&rft.issue=13&rft.spage=3125&rft.epage=3128&rft.pages=3125-3128&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E75807158%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75807158&rft_id=info:pmid/8319220&rfr_iscdi=true